According to the company, it is anticipating cost savings of up to $300 million through 2024, which includes an estimated 25% reduction in current workforce and a reduction in external expenses. (Image Credit: Rawpixel.com – Adobe.Stock.com)
Apellis Pharmaceuticals Inc announced a corporate restructuring to drive growth of pegcetacoplan injection (SYFOVRE) and pegcetacoplan (EMPAVELI), which the company said in a release would “position it for long-term success.”
According to a company news release, the planned restructuring will include cost reduction initiatives that align with the companys near-term priorities and are expected to result in up to $300 million in total cost savings through 2024.
Cedric Francois, MD, PhD, co-fo…
Read the full article at: https://www.modernretina.com/view/apellis-announces-corporate-restructuring-to-drive-growth-of-pegcetacoplan